These findings led to the subsequent United States Food and Drug Administration approval of anastrozole as adjuvant therapy for postmenopausal women with hormone receptor positive early breast cancer, and widespread adoption of the practice of prescribing initial anastrozole therapy for many women with early breast cancer. Here, NR4A1 is linked to breast cancer.